Media Thread, page-1185

As we have said for quite some time,
"when the penny drops" ,
a valuation that reflects future revenues across the platforms will start to build. Proof of concept for the first B Cell vaccine is essentially proof of concept for many more to follow.

Davy: "We are also definitely (in my view) "undervalued" and "not well understood by the market."

Have you given much consideration Dave to a break down of "Sum of the Parts" Total Valuation ?

At today's price based off the Turnstone/Takeda pre clinical deal CF33 might be considered valued at half fair value. Leaving the further advanced HerVax at late stage Ph 2 , and Pd1 Vaxx with preliminary Ph1 safety showing ,valued at zero. Absurd really. All are game changers.

Personally i don't see any upside or understanding from the Mimitope platform factored in at this level.